Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Rothenberg

Showing results (141-150 of 162) with videos related to

Pageof 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 1998
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposideL A Hammond, J R Eckardt, R Ganapathi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trialMace L Rothenberg, Amit M Oza, Robert H Bigelow, et al.
Gynecologic Oncology|December 8, 2004
Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group studyMace L Rothenberg, P Y Liu, Sharon Wilczynski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1996
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerM L Rothenberg, M J Moore, M C Cripps, et al.
International Journal of Nanomedicine|February 25, 2015
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|February 14, 2008
TGF-beta signalling-related markers in cancer patients with bone metastasisJose Baselga, Mace L Rothenberg, Josep Tabernero, et al.
The Oncologist|January 18, 2007
The continuum of care: a paradigm for the management of metastatic colorectal cancerRichard M Goldberg, Mace L Rothenberg, Eric Van Cutsem, et al.
Cancer|March 26, 1999
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinomaM L Rothenberg, J V Cox, R F DeVore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2023
Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized TrialH A Burris, M J Moore, J Andersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialH A Burris, M J Moore, J Andersen, et al.
Pageof 17

Showing results (141-150 of 162) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 1998
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposideL A Hammond, J R Eckardt, R Ganapathi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trialMace L Rothenberg, Amit M Oza, Robert H Bigelow, et al.
Gynecologic Oncology|December 8, 2004
Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group studyMace L Rothenberg, P Y Liu, Sharon Wilczynski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1996
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerM L Rothenberg, M J Moore, M C Cripps, et al.
International Journal of Nanomedicine|February 25, 2015
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|February 14, 2008
TGF-beta signalling-related markers in cancer patients with bone metastasisJose Baselga, Mace L Rothenberg, Josep Tabernero, et al.
The Oncologist|January 18, 2007
The continuum of care: a paradigm for the management of metastatic colorectal cancerRichard M Goldberg, Mace L Rothenberg, Eric Van Cutsem, et al.
Cancer|March 26, 1999
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinomaM L Rothenberg, J V Cox, R F DeVore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2023
Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized TrialH A Burris, M J Moore, J Andersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialH A Burris, M J Moore, J Andersen, et al.
Pageof 17